On September 30, 2011, Kruger, Karin; Stegmann, George F.; Becker, Piet J. published an article.Reference of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride The title of the article was Preliminary investigation of concurrent administration of phenylbutazone and romifidine in healthy horses. And the article contained the following:
To characterize the cardiorespiratory and electrocardiog. effects of the combined administration of phenylbutazone and romifidine. Prospective four-period, four-treatment, blinded, randomized, crossover trial. Five, healthy, mixed breed horses. Prior to treatment administration, a catheter was introduced into the intra-thoracic cranial vena cava via the jugular vein and a s.c. located carotid artery was catheterised. All treatments were administered i.v. and consisted of saline placebo (PLC), phenylbutazone (PBZ, 4.4 mg/kg-1) romifidine (ROM, 80 μg/kg-1) and a combination of phenylbutazone (4.4 mg/kg-1) and romifidine (80 μg/kg-1). There was at least a 1 wk washout period between treatments. Heart rate (HR), respiratory rate (fR), systolic (SAP), diastolic (DAP) and mean (MAP) arterial pressures and central venous pressure (CVP) were recorded for baseline (prior to drug administration) and at 5 min intervals thereafter for 30 min. Electrocardiog. abnormalities were recorded. Data were analyzed by ANOVA. For the cardiovascular variables there were no statistically significant (p > 0.05) differences between horses treated with ROM and PBZ_ROM. Statistically significant (p < 0.05) differences only occurred between treatments with romifidine (ROM and PBZ_ROM) and without romifidine (PLC and PBZ). Within treatments, for ROM, changes over time were statistically significant (p < 0.05) for HR, SAP, DAP, MAP and CVP. For PBZ_ROM, changes over time were statistically significant (p < 0.05) for CVP. Sino-atrial and atrio-ventricular blocks occurred in horses treated with ROM and PBZ_ROM. The combined i.v. administration of phenylbutazone and romifidine had no statistically significant effect on cardiorespiratory variables. These limited data suggest no evidence why both agents should not be included in a preoperative medication protocol for healthy horses but do not exclude the possibility of interactions occurring in a larger population. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Reference of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride
The Article related to phenylarthrite sedivet anesthetic combination therapy heart rate respiration horse, Pharmacology: Drug Interactions and General Pharmacology and other aspects.Reference of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem